Drug data last refreshed 4h ago
FREAMINE 8.5% is an intravenous amino acid injection indicated for muscle atrophy and pressure ulcer treatment in patients requiring parenteral nutrition support. This legacy product provides essential amino acids to promote protein synthesis and tissue repair in hospitalized and critically ill populations.
As a legacy injectable approaching LOE with limited patent protection, this product is experiencing consolidation pressure; commercial teams are typically focused on market defense and cost management rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Effects of a Dialysis-Specific Formula Rich in Branched-Chain Amino Acids, Omega-3, and Dietary Fiber on Nutritional Status
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
The Glucagonotropic Effect of Amino Acids in Humans
Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)
Bioavailability of Plant Protein Amino Acids
Worked on FREAMINE 8.5% at B. Braun? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on FREAMINE 8.5% offers limited career acceleration; roles are primarily focused on defending market share, managing hospital relationships, and optimizing manufacturing costs in a declining category. This position is best suited for professionals seeking stability in a mature product environment or leveraging it as a stepping stone to higher-growth therapeutic areas.